Evidence map›Paper›PMID 26883695›Full record

ArticleAntimicrobial agents and chemotherapy2016

Phenotypically Adapted Mycobacterium tuberculosis Populations from Sputum Are Tolerant to First-Line Drugs.

Obolbek Turapov, Benjamin D O'Connor, Asel A Sarybaeva, Caroline Williams, Hemu Patel, Abdullaat S Kadyrov, Akpay S Sarybaev, Gerrit Woltmann, Michael R Barer, Galina V Mukamolova

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical Strains ofPathogens (Basel, Switzerland) · 2024
    Article
  4. Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  5. Eradication of Drug-TolerantMicroorganisms · 2023
    Review
  6. Antibiotics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Types and functions of heterogeneity in mycobacteria.Nature reviews. Microbiology · 2022
    Review
  13. Culture-Free Enumeration ofMicroorganisms · 2022
    Article
  14. Article
  15. Article
  16. Frontiers in cellular and infection microbiology · 2022
    Review
  17. Understanding the contribution of metabolism toFrontiers in cellular and infection microbiology · 2022
    Review
  18. Dimethyl fumarate eliminates differentially culturableFrontiers in cellular and infection microbiology · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Obolbek TurapovDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
Benjamin D O'ConnorDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
Asel A SarybaevaDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
Caroline WilliamsDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
Hemu PatelEmpath Pathology Services, Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
Abdullaat S KadyrovNational Center of Phthisiology, Akhunbaeva, Bishkek, Kyrgyzstan.
Akpay S SarybaevKyrgyz Indian Mountain Biomedical Research Center, Togolok Moldo, Bishkek, Kyrgyzstan.
Gerrit WoltmannDepartment of Respiratory Medicine, Glenfield Hospital, Leicester, United Kingdom.
Michael R BarerDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom Empath Pathology Services, Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
Galina V MukamolovaDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom gvm4@le.ac.uk.
University of Leicester · GBUniversity Hospitals of Leicester NHS Trust · GBGlenfield Hospital · GBNational Center of Cardiology and Internal Medicine · KG

Funding

Biotechnology and Biological Sciences Research Council BB/H008586/1Biotechnology and Biological Sciences Research Council BB/K000330/1Medical Research Council G0501435
6 · The paper itself

Abstract

Tuberculous sputum contains multipleMycobacterium tuberculosispopulations with different requirements for isolationin vitro These include cells that form colonies on solid media (plateableM. tuberculosis), cells requiring standard liquid medium for growth (nonplateableM. tuberculosis), and cells requiring supplementation of liquid medium with culture supernatant (SN) for growth (SN-dependentM. tuberculosis). Here, we describe protocols for the cryopreservation and direct assessment of antimicrobial tolerance of theseM. tuberculosispopulations within sputum. Our results show that first-line drugs achieved only modest bactericidal effects on all three populations over 7 days (1 to 2.5 log10reductions), and SN-dependentM. tuberculosiswas more tolerant to streptomycin and isoniazid than the plateable and nonplateableM. tuberculosisstrains. Susceptibility of plateableM. tuberculosisto bactericidal drugs was significantly increased after passagein vitro; thus, tolerance observed in the sputum samples from the population groups was likely associated with mycobacterial adaptation to the host environment at some time prior to expectoration. Our findings support the use of a simpleex vivosystem for testing drug efficacies against mycobacteria that have phenotypically adapted during tuberculosis infection.

Indexed as

Adaptation, PhysiologicalBiological AssayAntitubercular AgentsCryopreservationDrug Resistance, BacterialHumansIsoniazidMicrobial Sensitivity TestsMultilocus Sequence TypingMycobacterium tuberculosisPhenotypeSputumStreptomycinTuberculosis, PulmonaryAntitubercular AgentsIsoniazidStreptomycin

Identifiers

PMID26883695
PMCPMC4808147
OpenAlexW2284278433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.